4 research outputs found
The contexts of use and the innovation of TV-centric network technologies: as viewers become consumer-users
This thesis seeks to explore something of the current nature of human, social and business
contingencies constituting and motivating design, production, consumption and the use of
technologies. It places a particular emphasis on the innovation of TV-centric network technologies -
'new' media technologies, particularly interactive television (i-Tv), intended to link, enhance or
otherwise augment existing television technology and content. The empirical work in the thesis studied
the development and implementation of a complex large-scale i-Tv trial in Cambridge, UK. Issues
arising from the research led to the development of a general research framework - Contextual
Usability (CU) - whose central aim is to draw awareness to the complex and multiple dimensions of
the use process as a social and organisational construction, and also to redefine its place as an intrinsic
experiential dimension in the domestication of products and services.Various senior managers and designers were interviewed within the company designing and producing
the i-Tv technology and interface for the trial, as were 11 participant households. The author concludes
with an overview suggesting the interconnected and interdependent nature of trials, technology, users,
design, designers and organisation. For this he uses CU in relation to Molina's notion of
Sociotechnical Constituencies to illustrate how social, cultural and organisational elements of trials
both rely and impinge upon the implementation and interpretation of user and consumer research, and
thus working 'images'of the user and the use process
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
Importance: The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear.
Objective: To define patterns of recurrence after adjuvant chemotherapy and the association with survival.
Design, Setting, and Participants: Prospectively collected data from the phase 3 European Study Group for Pancreatic Cancer 4 adjuvant clinical trial, an international multicenter study. The study included 730 patients who had resection and adjuvant chemotherapy for pancreatic cancer. Data were analyzed between July 2017 and May 2019.
Interventions: Randomization to adjuvant gemcitabine or gemcitabine plus capecitabine.
Main Outcomes and Measures: Overall survival, recurrence, and sites of recurrence.
Results: Of the 730 patients, median age was 65 years (range 37-81 years), 414 were men (57%), and 316 were women (43%). The median follow-up time from randomization was 43.2 months (95% CI, 39.7-45.5 months), with overall survival from time of surgery of 27.9 months (95% CI, 24.8-29.9 months) with gemcitabine and 30.2 months (95% CI, 25.8-33.5 months) with the combination (HR, 0.81; 95% CI, 0.68-0.98; P = .03). The 5-year survival estimates were 17.1% (95% CI, 11.6%-23.5%) and 28.0% (22.0%-34.3%), respectively. Recurrence occurred in 479 patients (65.6%); another 78 patients (10.7%) died without recurrence. Local recurrence occurred at a median of 11.63 months (95% CI, 10.05-12.19 months), significantly different from those with distant recurrence with a median of 9.49 months (95% CI, 8.44-10.71 months) (HR, 1.21; 95% CI, 1.01-1.45; P = .04). Following recurrence, the median survival was 9.36 months (95% CI, 8.08-10.48 months) for local recurrence and 8.94 months (95% CI, 7.82-11.17 months) with distant recurrence (HR, 0.89; 95% CI, 0.73-1.09; P = .27). The median overall survival of patients with distant-only recurrence (23.03 months; 95% CI, 19.55-25.85 months) or local with distant recurrence (23.82 months; 95% CI, 17.48-28.32 months) was not significantly different from those with only local recurrence (24.83 months; 95% CI, 22.96-27.63 months) (P = .85 and P = .35, respectively). Gemcitabine plus capecitabine had a 21% reduction of death following recurrence compared with monotherapy (HR, 0.79; 95% CI, 0.64-0.98; P = .03).
Conclusions and Relevance: There were no significant differences between the time to recurrence and subsequent and overall survival between local and distant recurrence. Pancreatic cancer behaves as a systemic disease requiring effective systemic therapy after resection.
Trial Registration: Clinicaltrials.gov Identifier: NCT00058201, EudraCT 2007-004299-38, and ISRCTN 96397434